Cargando…

COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review

Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nas, Kemal, Eryilmaz, Nuran, Geyik, Mehmet Faruk, Altaş, Ayfer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Case Based Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897416/ https://www.ncbi.nlm.nih.gov/pubmed/33611657 http://dx.doi.org/10.1007/s00296-021-04809-3

Ejemplares similares

Colchicine-Resistant Familial Mediterranean Fever With Depressive State Successfully Treated With Escitalopram
por: Toshida, Masamitsu, et al.
Publicado: (2021)

Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review
por: Yıldırım, Derya, et al.
Publicado: (2023)

COVID-19 in patients with gout on colchicine
por: Pelechas, Eleftherios, et al.
Publicado: (2021)

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever
por: Calligaris, Lorenzo, et al.
Publicado: (2007)

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
por: El Hasbani, Georges, et al.
Publicado: (2019)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

The patient experience of Colchicine Resistant-Familial Mediterranean Fever (cr-FMF)
por: Dandekar, P, et al.
Publicado: (2015)

IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
por: Köhler, Birgit Maria, et al.
Publicado: (2018)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

Menorrhagia due to uterine amyloidosis in familial Mediterranean fever: case-based review
por: Cansu, Döndü Üsküdar, et al.
Publicado: (2020)

Comparison of Different Pharmaceutical Preparations of Colchicine in Children with Familial Mediterranean Fever: Is Colchicine Opocalcium a Good Alternative?
por: Türkuçar, Serkan, et al.
Publicado: (2021)

Does switching from coated colchicine to compressed colchicine improves treatment response in patients with familial Mediterranean fever?
por: Öner, Nimet, et al.
Publicado: (2023)

The impact of COVID-19 on familial Mediterranean fever: a nationwide study
por: Günendi, Zafer, et al.
Publicado: (2021)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

Intestinal malrotation as a misdiagnosis of pediatric colchicine resistant familial Mediterranean fever
por: Heshin-Bekenstein, Merav, et al.
Publicado: (2015)

Epidemiology of colchicine resistant Familial Mediterranean Fever disease (CrFMF) in Turkey
por: Turgay, S, et al.
Publicado: (2015)

Chemotherapy-Colchicine Interaction in a Child with Familial Mediterranean Fever and Hodgkin Lymphoma
por: Langenberg-Ververgaert, Karin P.S., et al.
Publicado: (2018)

Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever
por: Verrecchia, E., et al.
Publicado: (2017)

Remission of nephrotic syndrome in amyloidosis of familial Mediterranean fever following colchicine treatment
por: Odabas, Hatice
Publicado: (2006)

A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever
por: Corsia, Alice, et al.
Publicado: (2017)

Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
por: Omma, Ahmet, et al.
Publicado: (2021)

Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review
por: Talerico, Rosa, et al.
Publicado: (2020)

Appendectomy history is associated with severe disease and colchicine resistance in adult familial Mediterranean fever patients
por: BODAKÇİ, Erdal, et al.
Publicado: (2021)

Effect of oral Colchicine on Peripapillary retinal nerve fiber layer thickness in patients with familial Mediterranean fever
por: Tanyıldız, Burak, et al.
Publicado: (2018)

Neurological Face of Familial Mediterranean Fever
por: Bektaş, Polat Cengiz, et al.
Publicado: (2022)

Coexistence of hereditary angioedema in a case of familial Mediterranean fever with partial response to colchicine
por: Bahceci, Semiha Erdem, et al.
Publicado: (2015)

Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?
por: Omma, Ahmet, et al.
Publicado: (2017)

Genotype Mutations in Egyptian Children with Familial Mediterranean Fever: Clinical Profile, and Response to Colchicine
por: Talaat, Hala S., et al.
Publicado: (2020)

Risk factors for subclinical inflammation in children with familial mediterranean fever
por: Soylu, Alper, et al.
Publicado: (2014)

Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra
por: Celebi, Zeynep Kendi, et al.
Publicado: (2014)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
por: Karabulut, Yusuf, et al.
Publicado: (2022)

Colchicine-induced rhabdomyolysis following a concomitant use of clarithromycin in a haemodialysis patient with familial Mediterranean fever
por: Çelebi, Zeynep Kendi, et al.
Publicado: (2013)

Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis
por: Sargin, Gokhan, et al.
Publicado: (2019)

Long-term use of colchicine: “The time to guard against chronic toxicity among patients of familial Mediterranean fever”
por: Emara, Mohamed H., et al.
Publicado: (2023)

Clinical features, functional status, and quality of life in patients with late-onset familial Mediterranean fever
por: Gursoy, Didem Erdem, et al.
Publicado: (2023)

PReS-FINAL-2195: The comparison of the efficacy of once and twice daily dosage of colchicine in pediatric patients with Familial Mediterranean Fever
por: Polat, A, et al.
Publicado: (2013)

Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study
por: Ben-Zvi, Ilan, et al.
Publicado: (2014)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lg3pj1pi2lgihalalbgbp505k6